Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2005

View Archived Issues

Neuroprotective effects of IBU-PO, a novel bifunctional NSAID-cholinesterase inhibitor

Glycine transport inhibitors modulate dopamine in vitro

In vitro and in vivo pharmacology of the novel iNOS inhibitor FR-260330

Cytotoxic effects of telomerase inhibition with BIBR-1532 in leukemia cells

MedImmune amends ex-U.S. RSV agreement with Abbott

Tercica submits NDA for Increlex

Elusys files IND to begin human safety studies of Anthim

New phase II study to test TB4 for epidermolysis bullosa

BioPro takes Asia-Pacific rights to Vantas

Debiopharm purchases outstanding shares of H3 Pharma

Ono updates progress of ONO-2506 and inlicensed Merck compounds

Hexvix approved in 26 European countries

Enrollment open in phase II study of PTK/ZK in NSCLC

New phase II study for NeuroVax

Bionomics completes acquisition of Neurofit

Geron and BRC create new company for telomerase activation therapies

Valeant completes Xcel acquisition

Pivotal trial begins for FK-228 for CTCL

Procyon Biopharma grants Medicorp rights to PSP94-based test kits

Phase II data support the use of SPP-301 in diabetic nephropathy

NRP-104 reported effective in the treatment of ADHD

ALVAC vCP1452 shows efficacy in preventing viral rebound in HIV-infected patients

MVA-nef induces a strong specific immune response in HIV-infected patients

S-236 cream effective in pruritis, xerosis and atopic dermatitis in humans

Topical compound containing MMP and PKC inhibitors improves skin hypersensitivity in humans

New title added to the Drug R&D Backgrounders topic list - Autism Spectrum Disorders

Controlled release formulations for antiinfective therapy claimed

Two series of serotonin reuptake inhibitors reported by Merck

Novel anti-hepatitis C virus (HCV) agents discovered at Enanta

Celltech discloses the development of novel p38 MAP kinases for rheumatoid arthritis

New immunoglobulin E (IgE) production inhibitors and their use disclosed by Celltech